20 research outputs found
Cyanobacterial lipopolysaccharides and human health – a review
Cyanobacterial lipopolysaccharide/s (LPS) are frequently cited in the cyanobacteria literature as toxins responsible for a variety of heath effects in humans, from skin rashes to gastrointestinal, respiratory and allergic reactions. The attribution of toxic properties to cyanobacterial LPS dates from the 1970s, when it was thought that lipid A, the toxic moiety of LPS, was structurally and functionally conserved across all Gram-negative bacteria. However, more recent research has shown that this is not the case, and lipid A structures are now known to be very different, expressing properties ranging from LPS agonists, through weak endotoxicity to LPS antagonists. Although cyanobacterial LPS is widely cited as a putative toxin, most of the small number of formal research reports describe cyanobacterial LPS as weakly toxic compared to LPS from the Enterobacteriaceae. We systematically reviewed the literature on cyanobacterial LPS, and also examined the much lager body of literature relating to heterotrophic bacterial LPS and the atypical lipid A structures of some photosynthetic bacteria. While the literature on the biological activity of heterotrophic bacterial LPS is overwhelmingly large and therefore difficult to review for the purposes of exclusion, we were unable to find a convincing body of evidence to suggest that heterotrophic bacterial LPS, in the absence of other virulence factors, is responsible for acute gastrointestinal, dermatological or allergic reactions via natural exposure routes in humans. There is a danger that initial speculation about cyanobacterial LPS may evolve into orthodoxy without basis in research findings. No cyanobacterial lipid A structures have been described and published to date, so a recommendation is made that cyanobacteriologists should not continue to attribute such a diverse range of clinical symptoms to cyanobacterial LPS without research confirmation
Ionic and pH signalling to shoots of flooded tomato plants in relation to stomatal closure
Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study.
Purpose
Few options are available for pain relief in patients with bone metastases who fail standard treatments.
We sought to determine the benefit of radiofrequency ablation (RFA) in providing pain relief for patients
with refractory pain secondary to metastases involving bone.
Patients and Methods
Thirty-one US and 12 European patients with painful osteolytic metastases involving bone were treated
with image-guided RFA using a multitip needle. Treated patients had
4/10 pain and had either failed
or were poor candidates for standard treatments such as radiation or opioid analgesics. Using the Brief
Pain Inventory–Short Form, worst pain intensity was the primary end point, with a 2-unit drop considered
clinically significant.
Results
Forty-three patients were treated (median follow-up, 16 weeks). Before RFA, the mean score for worst
pain was 7.9 (range, 4/10 to 10/10). Four, 12, and 24 weeks following treatment, worst pain decreasedto 4.5 (P0001), 3.0 (P
0001), and 1.4 (ìP.0005), respectively. Ninety-five percent (41 of 43
patients) experienced a decrease in pain that was considered clinically significant. Opioid usage
significantly decreased at weeks 8 and 12. Adverse events were seen in 3 patients and included (1) a
second-degree skin burn at the grounding pad site, (2) transient bowel and bladder incontinence
following treatment of a metastasis involving the sacrum, and (3) a fracture of the acetabulum following
RFA of an acetabular lesion.
Conclusion
RFA of painful osteolytic metastases provides significant pain relief for cancer patients who have failed
standard treatment